Axsome Therapeutics AXSM Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 92.6%+1.2pp | 91.4%+1.0pp | 90.4%+0.8pp | 89.6%— | |
| Operating margin | -26.1%+46.6pp | -72.7%+12.9pp | -85.7%+274pp | -359.3%— | |
| Net margin | -28.7%+45.8pp | -74.5%+13.9pp | -88.4%+286pp | -374%— | |
| Returns | |||||
| Return on equity | -252.1%-20.5pp | -231.6%-72.4pp | -159.2%+140pp | -299%-97.5pp | |
| Efficiency | |||||
| Asset turnover | 1×+0.3× | 0.7×+0.1× | 0.6×+0.3× | 0.2×— | |
| Liquidity | |||||
| Current ratio | 1.6×-0.6× | 2.1×-1.5× | 3.6×+1.1× | 2.5×-1.2× | |
| Leverage | |||||
| Debt-to-equity | 2.5×-0.9× | 3.4×+2.4× | 1×+0.1× | 0.9×-2.3× | |
| Per Share | |||||
| Book value per share | $1.77+49.2% | $1.19-71.7% | $4.20+56.0% | $2.69+549% | |
| Valuation | |||||
| Market capitalization | $9.21B+125% | $4.1B+8.9% | $3.77B+12.4% | $3.35B+131% | |
| Price / sales | 14.4×+3.8× | 10.6×-3.3× | 13.9×-53.1× | 67×— | |
| Price / book | 104.3×+32.4× | 71.9×+52.2× | 19.7×-10.9× | 30.6×-62.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Axsome Therapeutics's profit margins?
- Axsome Therapeutics (AXSM) runs a 92.6% gross margin and a -24.4% operating margin, with a -26.6% net margin.
- Where do Axsome Therapeutics's ratios come from?
- Every ratio is computed from Axsome Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
